Skyai, Inc. quarterly report, Q1 FY2025

Business Context and Reporting Period

Company: Sharps Technology, Inc. (Note: Input metadata referenced "Skyai, Inc.", but the filing text identifies the registrant as Sharps Technology, Inc., ticker STSS).

Reporting Period: Quarter ended March 31, 2025 (Form 10-Q).

Business Overview: Sharps is a pre-revenue medical device company focused on safety syringes and pharmaceutical packaging. It operates a manufacturing facility in Hungary and is currently transitioning from R&D to commercialization. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.

Key Financial Metrics

Metric Q1 2025 Q1 2024
Revenue $0 $0
Net Income (Loss) $1,928,834 $(982,386)
Operating Expenses $(2,021,769) $(1,844,052)
Cash and Cash Equivalents $11,894,937 $1,165,913
Working Capital $5,598,222 $(2,011,679)
Debt (Notes Payable) $0 $3,763,622
Warrant Liability $7,781,658 $98,913

Cash Flow Summary (Q1 2025):

  • Operating Activities: Net cash used of $2,450,564.
  • Investing Activities: Net cash used of $473,658 (primarily fixed assets and deposits).
  • Financing Activities: Net cash provided of $13,953,031 (driven by $18.2M net proceeds from equity offering, offset by $4.2M debt repayment).

Material Changes vs. Prior Period

  • Profitability Shift: The company reported a net income of $1.93M in Q1 2025 compared to a net loss of $0.98M in Q1 2024. This turnaround is primarily non-operational, driven by a $4.62M fair value (FMV) gain on warrant liabilities, offsetting operating losses and interest expenses.
  • Liquidity Transformation: Cash balances increased from $0.86M to $11.89M following a $20M gross equity offering in January 2025. Concurrently, the company repaid all outstanding notes payable, leaving it debt-free.
  • Expense Trends: General and Administrative (G&A) expenses increased by 18% ($293k) due to higher payroll (including CEO bonuses tied to the offering) and professional fees. R&D expenses decreased by 58% ($115k) as focus shifted toward manufacturing.
  • Capital Structure: Significant changes in equity occurred due to a 1-for-300 reverse stock split effective April 2025 (reflected in share counts) and the issuance of new warrants (Series A and B) in the 2025 offering.

Outlook, Risks, and Contingencies

Guidance and Outlook: Management expects to transition to revenue in the second half of 2025. A supply agreement with Stericare Solutions for 520 million syringe units (potential revenue >$50M) was signed, with an initial purchase order of $400k received in April 2025. The company plans to use recent capital to expand production capacity in Hungary.

Risks and Contingencies:

  • Going Concern: Despite the recent cash infusion, management states that current working capital may not be sufficient to fund operations for the next 12 months without further financing or successful commercialization.
  • Nasdaq Compliance: The company received notices of non-compliance regarding minimum bid price and stockholders' equity requirements. While the Q1 2025 equity balance ($10.1M) meets the $2.5M threshold, the company is awaiting a hearing decision regarding continued listing.
  • Legal Proceedings:
    • Berler Lawsuit: Former CTO Barry Berler sued for ~$456k in unpaid fees/bonuses and claims to 50% of Series A Preferred Stock. The company has accrued for unpaid fees but disputes other claims.
    • Plastomold Lawsuit: Supplier Plastomold sued for $1.76M regarding unpaid invoices and defective machinery. The company has filed counterclaims alleging insufficient services.
  • Commercialization Delays: The "Provensa" product line faces delays due to design optimization needs, with no timeline for final commercialization.

Investor Verification Checklist

  • Revenue Recognition: Verify the timing and terms of the Stericare supply agreement to confirm when the $50M+ revenue potential will be recognized.
  • Warrant Liability Volatility: Monitor the fair value adjustments of the $7.8M warrant liability, as fluctuations significantly impact reported net income/loss.
  • Nasdaq Status: Confirm the outcome of the Nasdaq hearing regarding minimum bid price and equity compliance to assess delisting risk.
  • Legal Reserves: Review the status of the Berler and Plastomold litigation to determine if additional accruals or settlements are required.
  • Cash Burn Rate: Assess the sustainability of the $2.45M quarterly operating cash burn against the $11.9M cash balance to validate the runway for commercialization.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.